Positron emission tomography (PET) study with (11C) flumazenil to determine central GABAA receptor occupancy of AZD6280 - PET

Study identifier:D0850C00011

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An open label positron emission tomography (PET) study with (11C)flumazenil to determine central GABAA receptor occupancy of AZD6280 after oral administration to healthy volunteers

Medical condition

Anxiety

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD6280, (11C) flumazenil

Sex

Male

Actual Enrollment

8

Study type

Interventional

Age

20 Years - 45 Years

Date

Study Start Date: 01 Feb 2008
Primary Completion Date: 01 Sept 2008
Study Completion Date: 01 Sept 2008

Study design

Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2008 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria